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Available online 7 June 2016Background: Gastrointestinal (GI) events are common in postmenopausal women treated for osteoporosis. The
inﬂuence of GI events on treatment initiation and treatment compliance is the subject of ongoing research.
Objective: The objectives of this studywere (i) to determine the association of GI eventswith receipt of treatment
in patients newly diagnosed with osteoporosis, and (ii) among treated patients, to determine the association of
GI events with treatment compliance.
Methods: This was a retrospective analysis of claims data carried out in Germany using the Mediplus database.
Data were collected from January 1992 through December 2010. The dual-objective study design required two
distinct cohorts. Cohort 1 comprisedwomen aged ≥55with a diagnosis of osteoporosis. GI events were recorded
for the 12month periods before and after the date of diagnosis. Time-varying Cox regression and discrete choice
models were used, respectively, to assess the association of post-diagnosis GI events with the initiation of phar-
macologic treatment (yes versus no) and the type of treatment initiated (bisphosphonates versus non-
bisphosphonates). Cohort 2 comprised women aged ≥55 who initiated an oral bisphosphonate (alendronate,
ibandronate, or risedronate). GI events were recorded for the 12 month periods before and after the date of bis-
phosphonate initiation, and a logistic regression model was employed to determine if pre-treatment or post-
treatment GI events were associated with patient compliance, deﬁned as a medication possession ratio (MPR)
of ≥60%, with sensitivity analyses at MPR ≥ 80%.
Results: In cohort 1 (N= 18,813), 13.8% of patients had GI events in the pre-diagnosis period, and 14.8% had GI
events in thepost-diagnosis period. Among the patientswith post-diagnosis GI events, 93.2% remaineduntreated
during the post-index year, 6.2% were treated with bisphosphonates, and 0.6% received non-bisphosphonates.
The respective percentages in patients without post-diagnosis GI events were 81.3%, 16.7%, and 1.9%. A post-
diagnosis GI event decreased the likelihood of receiving any osteoporosis treatment (versus no treatment) by
83% (HR 0.17, 95% CI 0.14–0.20) and also decreased the likelihood of receiving a bisphosphonate (versus a
non-bisphosphonate) by 39% (OR 0.61, 95% CI 0.54–0.68). In cohort 2 (N=6040), 17.1% of patients hadGI events
in theyearbefore treatment initiation, and19.1%hadGI events in the year after treatment initiation.At 12months
post-treatment initiation, GI eventsweremore frequent in patients with pre-treatment GI events (53.2%) than in
those without pre-treatment GI events (12.0%). Post-treatment GI events decreased the likelihood of attaining
compliance deﬁned as an MPR ≥ 60% (OR 0.84, 95% CI 0.73–0.97) but not an MPR ≥ 80% (OR 0.91, 95% CI 0.79–
1.06).
Conclusions: In Germanwomen newly diagnosedwith osteoporosis, GI events decreased the likelihood of receiv-
ing treatment andwere associatedwith the choice of treatment. In women initiating oral bisphosphonates, post-
treatment GI events were associated with reduced patient compliance.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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en access article under the CC BY-NC1. Introduction
Osteoporosis is present in an estimated 25% of women aged ≥50 in
Germany (Gauthier et al., 2012). Findings from a national analysis of
medical claims indicated that, among German patients being treated
pharmacologically for osteoporosis, approximately half were prescribed
oral bisphosphonates (Haussler et al., 2007).-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
209A. Modi et al. / Bone Reports 5 (2016) 208–213Gastrointestinal (GI) symptoms (e.g., heartburn, reﬂux, nausea,
vomiting) have been observed in up to 52% of German users of
bisphosphonates (primarily women over age 45) (Ringe and Moller,
2009; Bauer et al., 2012), but GI symptoms are common among post-
menopausal women (Freemantle et al., 2010; Infantino, 2008), making
it difﬁcult to ascribe such symptoms to bisphosphonate use. Indeed, ob-
servational case-control studies have demonstrated that there is no sig-
niﬁcant relationship between bisphosphonate use and upper GI
complications (Etminan et al., 2009; Vestergaard et al., 2010; Ghirardi
et al., 2014). Nevertheless, GI adverse events (or the use of
gastroprotective agents) have often been found to be associated with
lower rates of compliance with osteoporosis therapy (Rossini et al.,
2006; Penning-van Beest et al., 2008; Gallagher et al., 2008), and GI
problems may affect the decision to treat osteoporosis (Colon-Emeric
et al., 2007).
The impact of GI events on treatment decisions and patient compli-
ance has not been studied in Germany. The objectives of this studywere
therefore (i) to determine whether GI events were associated with the
decision to treat and the choice of treatment in female osteoporosis pa-
tients in Germany, and (ii) among treated patients, to estimate the asso-
ciation of GI events with compliance while on treatment.
2. Materials and methods
2.1. Data source and study design
Data for this analysis were abstracted from theMediplus database of
Germany, a longitudinal physician-based database containing demo-
graphic, medical, pharmaceutical, and lab test results for patients. The
database is representative of the German population with regard to
the regional distribution of physicians, prescriptions, and diagnostic
groups of patients.
Each objective required a distinct patient cohort and study design
based on distinct index events. For objective 1, the index eventwas a di-
agnosis of osteoporosis, and subjects identiﬁed with this index event
were deﬁned as cohort 1. In this cohort, we observed GI events in the
post-index period up until treatment initiation, for a maximum time
of 12 months, and assessed the association of post-index GI events
with the odds of treatment initiation and choice of treatment. For objec-
tive 2, the index event was the initiation of an oral bisphosphonate, and
subjects identiﬁed with this event were deﬁned as cohort 2. For this co-
hort, we estimated the proportion of patients with GI events at 3, 6, and
12 months following the index date and assessed the association of
post-index GI events with patient compliance as of the 12-month time
point.
2.2. Study samples and variables
All subjects in the analysis werewomen aged ≥55 years on the index
date. Women who were diagnosed with a malignant neoplasm (Inter-
national Classiﬁcation of Diseases [ICD]-10 codes C00-C42, C44-C96,
D00-D09, and D37-D49) or Paget's disease (ICD-10 codeM88) were ex-
cluded from this study.
In cohort 1, womenwere selected who: received a diagnosis of oste-
oporosis on an index date between January 1, 1993 and December 31,
2009; were naïve to osteoporosis medication any time prior to the
index date and to estrogen for one year prior to the index date; and
had ≥12 months of continuous eligibility before and after the index
date. An osteoporosis diagnosis was deﬁned by the presence of an
ICD-10 code of M80 (osteoporosis with current pathological fracture)
or M81 (osteoporosis without current pathological fracture). Osteopo-
rosis medications were deﬁned as either bisphosphonates or non-
bisphosphonates and were identiﬁed in the data registry by their Ana-
tomical Therapeutic Chemical codes. The bisphosphonates were
alendronate, ibandronate, risedronate, and zoledronate, and the non-
bisphosphonates were calcitonin, raloxifene, strontium ranelate, andteriparatide/parathyroid hormone. Both oral and injectable forms of
all drugs were considered. GI events were identiﬁed by ICD-10 codes
(see Supplementary Table S1) and included nausea/vomiting; dyspha-
gia; esophagitis; gastroesophageal reﬂux disease; ulcer, stricture, perfo-
ration, or hemorrhage of the esophagus; gastric, duodenal, or peptic
ulcers; acute gastritis; duodenitis; and GI hemorrhage. Pre-diagnosis
GI events were assessed in the 1-year pre-index period. Post-diagnosis
GI events were assessed from the index date until treatment initiation
or the end of follow-up, whichever came ﬁrst.
In cohort 2, women were selected who initiated a single oral bis-
phosphonate on an index date within the period 1996–2009, had
≥12 months of continuous eligibility before and after the index date,
and were naïve to all osteoporosis medications in the year before the
index prescription. Oral bisphosphonates of interest were alendronate,
ibandronate, and risedronate, and GI events were the same as those
listed for cohort 1. Compliance was deﬁned as a medication possession
ratio (MPR; the percentage of days in the post-index period on which
patients were in possession of the prescribed medication) of ≥60%,
with sensitivity analyses at MPR ≥ 80%.
2.3. Statistical analysis
Demographic and clinical characteristics (e.g., age; pre-index medi-
cation use (non-steroidal anti-inﬂammatory drugs [NSAIDs],
gastroprotective agents, and glucocorticoids), fractures, and GI events;
comorbidity proﬁles) were analyzed descriptively and are presented
as numbers and percentages or means and standard deviations, as
appropriate.
For cohort 1, the distribution of receipt of treatment and type of
treatment was compared across the subgroups with and without GI
events using a chi-square test. When quantifying the association of
post-diagnosis GI events with treatment, a two-stage analysis
accounted for the varying exposure time between the osteoporosis di-
agnosis and treatment initiation. In the ﬁrst stage, a time-dependent
Cox regression model was used to estimate the odds of receiving any
treatment versus no treatment. In this model, patients were stratiﬁed
according to the presence or absence of pre-diagnosis GI events. In the
second stage, a discrete choice model with a conditional logit was
used to estimate the odds of receiving bisphosphonates versus non-
bisphosphonates. For both models, the independent variables included
post-diagnosis GI events, age group, Deyo-Charlson comorbidity index
(CCI) score, common comorbidities, and pre-diagnosis medication use.
In the second model, pre-diagnosis GI events were added to the list of
independent variables.
In cohort 2, the frequency of post-treatment GI events in patients
with and without pre-treatment GI events was compared descriptively
at 3, 6, and 12 months post-index. Logistic regression was used to esti-
mate the odds of medication compliance. Independent variables includ-
ed in this model were pre-treatment and post-treatment GI events, age
group, pre-treatment medication use, pre-treatment osteoporosis-
related fractures, and CCI score.
3. Results
3.1. Association of GI events with treatment for osteoporosis
A total of 18,813womendiagnosedwith osteoporosiswere included
in cohort 1 (Table 1). The average age in this cohort was 71.4 years. Dur-
ing the pre-diagnosis period, 35.3% of the patients used NSAIDs and
16.9% used glucocorticoids, 18.1% used gastroprotective agents, and
13.8% experienced a GI event. The mean (SD) CCI score was 0.79
(1.11), and the most common comorbidity was hypertension (42.8%).
Among patients diagnosedwith osteoporosis, 3181 (16.9%) received
pharmacotherapy in the year following the diagnosis (Table 2).
Bisphosphonates were prescribed to 89.8% of treated patients and
non-bisphosphonates to 10.2%. Alendronate was the most frequently
Table 1
Baseline characteristics of patients.
Cohort 1: Cohort 2:
Patients diagnosed
with
osteoporosisa
Patients initiating
bisphosphonatesa
(N = 18,813) (N = 6040)
Age at the index date, mean (SD)b 71.4 (9.2) 73.3 (8.6)
Age distribution
55–64 4751 (25.3) 1021 (16.9)
65–74 6902 (36.7) 2170 (35.9)
75–84 5578 (29.7) 2303 (38.1)
≥85 1582 (8.4) 546 (9.0)
Pre-index medication useb
Gastroprotective agents 3408 (18.1) 1746 (28.9)
Proton pump inhibitors 2617 (13.9) 1500 (24.8)
H2 receptor antagonists 949 (5.0) 342 (5.7)
Cytoprotectants 54 (0.3) 18 (0.3)
NSAIDs 6644 (35.3) 2769 (45.8)
Glucocorticoids 3170 (16.9) 1399 (23.2)
Estrogen – 107 (1.8)
Pre-index GI eventsb 2601 (13.8) 1033 (17.1)
Pre-index OP-related fracturesb 663 (3.5) 554 (9.2)
OP-related fractures by site
Hip 158 (0.8) 138 (2.3)
Vertebral 241 (1.3) 317 (5.3)
Non-vertebral 279 (1.5) 130 (2.2)
Deyo-Charlson comorbidity index,
mean (SD)
0.79 (1.11) 0.87 (1.16)
Common OP-related comorbiditiesc
Hypertension 8053 (42.8) –
Depression 2228 (11.8) –
Diabetes 1335 (7.1) –
GI mucositis & urination problems 687 (3.7) –
Chronic inﬂammatory joint disease 546 (2.9) –
Fatigue 328 (1.7) –
Chronic kidney disease 119 (0.6) –
Chronic inﬂammatory bowel disease 88 (0.5) –
Hyperparathyroidism 24 (0.1) –
Vitamin D deﬁciency 6 (0.03) –
Celiac disease 3 (0.02) –
GI, gastrointestinal; NSAIDs, non-steroidal anti-inﬂammatory drugs; OP, osteoporosis; SD,
standard deviation.
a Values are presented as N (%) unless indicated otherwise.
b The index date was the date of osteoporosis diagnosis for cohort 1 and the date of
initiation of an oral bisphosphonate for cohort 2.
c Comorbidities were not collected for cohort 2.
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risedronate (22.9%), ibandronate (3.3%), and zoledronate (0.2%). Ralox-
ifene was the most commonly prescribed non-bisphosphonate (5.7%).
The average time from diagnosis to treatment was 47.1 days for
bisphosphonates and 40.6 days for non-bisphosphonates.Table 2
Distribution of osteoporosis treatments in cohort 1a.
Among all patients Among treated patients
(N = 18,813) (N = 3181)
No treatment 15,632 (83.1) –
Bisphosphonates 2856 (15.2) 2856 (89.8)
Alendronate 2017 (10.7) 2017 (63.4)
Ibandronateb 105 (0.6) 105 (3.3)
Risedronate 729 (3.9) 729 (22.9)
Zoledronateb 5 (0.03) 5 (0.2)
Non-bisphosphonates 325 (1.7) 325 (10.2)
Strontium 75 (0.4) 75 (2.4)
Calcitonin 70 (0.4) 70 (2.2)
Raloxifene 180 (1.0) 180 (5.7)
Teriparatide 0 (0.0) 0 (0.0)
Parathyroid hormone 0 (0.0) 0 (0.0)
a Values are presented as N (%). Treatment categories are mutually exclusive.
b Includes all injectable and infusion forms.The treatment distribution differed between patientswith andwith-
out post-diagnosis GI events (P b 0.001; Fig. 1). Among the patientswith
post-diagnosis GI events (N= 2789, 14.8%), 93.2% remained untreated,
6.2% were treated with bisphosphonates, and 0.6% received non-
bisphosphonates. The respective percentages in patients without post-
diagnosis GI events (N = 16,024) were 81.3%, 16.7%, and 1.9%.
Post-diagnosis GI events were associated with an 83% lower likeli-
hood of osteoporosis treatment (HR 0.17, 95% CI 0.14–0.20; Table 3).
In contrast, use of gastroprotective agents in the pre-diagnosis period
was predictive of treatment for osteoporosis (HR 1.62, 95% CI 1.48–
1.77). Several individual comorbidities were associated with an in-
creased likelihood of receiving treatment (HR 1.24 [95% CI 1.15–1.33]
for hypertension, 1.18 [95% CI 1.02–1.35] for diabetes, and 1.27 [95% CI
1.06–1.53] for chronic inﬂammatory joint disease), but a higher CCI
score was associated with lower likelihood of treatment (HR 0.94, 95%
CI 0.91–0.98). Other factors signiﬁcantly predictive of treatment for os-
teoporosis were older age (HR 1.27 [95% CI 1.16–1.40] for ages 65–74,
1.44 [95% CI 1.31–1.60] for ages 75–84, and 1.23 [95% CI 1.06–1.43] for
ages ≥85, compared to the reference group aged 55–64), NSAID use
(HR 1.29, 95% CI 1.20–1.38), and glucocorticoid use (HR 1.22, 95% CI
1.11–1.33).
Several factors were associated with a lower likelihood of receiving
bisphosphonate versus non-bisphosphonate therapy (Table 3). These
included pre- and post-diagnosis GI events (HR 0.85 [95% CI 0.78–
0.94] and 0.61 [95% CI 0.54–0.68], respectively), ages 75–84 years (HR
0.79, 95% CI 0.71–0.87) and ≥85 years (HR 0.72, 95% CI 0.54–0.97;
both versus age 55–64), and use of gastroprotective agents (HR 0.68,
95% CI 0.62–0.76).
3.2. Association of GI events with treatment compliance in patients initiat-
ing an oral bisphosphonate
A total of 6040 women who initiated an oral bisphosphonate were
included in cohort 2 (Table 1). The mean age in this cohort was
73.3 years. During the pre-treatment period, 45.8% of women used
NSAIDs, 23.2% used glucocorticoids, and 1.8% used estrogen. A total of
28.9% used gastroprotective agents, and 17.1% experienced a GI event.
Post-treatment GI events occurred more frequently in patients with
pre-treatment GI events (30.8%, 41.1%, and 53.2% at 3, 6, and 12months,
respectively) than in patients without pre-treatment GI events (4.4%,
7.0%, and 12.0%, respectively; Fig. 2). Overall, 19.1% of patients experi-
enced GI events in the year after initiating an oral bisphosphonate.
Patients experiencing GI events post-treatment initiation were less
likely than those not experiencing such events to exhibit compliance
at MPR ≥ 60% (OR 0.84, 95% CI 0.73–0.97; Table 4). Use of NSAIDs and
the occurrence of osteoporosis-related fractures in the pre-treatment
period increased the odds of being compliant at MPR ≥ 60% (OR 1.15
[95% CI 1.04–1.27] for NSAIDs; OR 1.21 [95% CI 1.01–1.45] for fractures).
In the sensitivity analyses, none of these variables were predictive ofFig. 1. Osteoporosis treatment in patients with and without post-diagnosis GI eventsa. GI,
gastrointestinal. aP b 0.001 for the different treatment distributions of patients with and
without post-diagnosis GI events.
Table 3
Likelihood of osteoporosis treatment (any versus none) and of receiving bisphosphonate
versus non-bisphosphonate therapy in patients diagnosed with osteoporosis.
Any treatment
versus
nonea
Bisphosphonate
versus
non-bisphosphonatea
Hazard
ratio
95% CI Odds
ratio
95% CI
Post-diagnosis GI event 0.17 0.14–0.20 0.61 0.54–0.68
Pre-diagnosis GI eventb – – 0.85 0.78–0.94
Age group (reference 55–64)
65–74 1.27 1.16–1.40 0.96 0.87–1.06
75–84 1.44 1.31–1.60 0.79 0.71–0.87
≥85 1.23 1.06–1.43 0.72 0.54–0.97
Pre-diagnosis medication use
Gastroprotective agents 1.62 1.48–1.77 0.68 0.62–0.76
NSAIDs 1.29 1.20–1.38 1.07 0.97–1.17
Glucocorticoids 1.22 1.11–1.33 0.98 0.88–1.09
Deyo-Charlson comorbidity index 0.94 0.91–0.98 0.96 0.92–1.01
Common OP-related comorbidities
Hypertension 1.24 1.15–1.33 1.06 0.97–1.15
Depression 0.93 0.83–1.03 1.11 0.94–1.31
Diabetes 1.18 1.02–1.35 1.22 1.05–1.41
GI mucositis & urination problems 0.94 0.78–1.14 0.86 0.75–0.99
Chronic inﬂammatory joint disease 1.27 1.06–1.53 1.05 0.95–1.17
Fatigue 1.12 0.86–1.45 1.04 0.93–1.16
Chronic kidney disease 1.31 0.89–1.92 0.90 0.64–1.28
Chronic inﬂammatory bowel
disease
1.10 0.71–1.72 0.99 0.65–1.51
Hyperparathyroidism 1.21 0.50–2.90 1.14 0.66–1.98
CI, conﬁdence interval; GI, gastrointestinal; NSAIDs, non-steroidal anti-inﬂammatory
drugs; OP, osteoporosis.
a Bold font indicates statistical signiﬁcance.
b The Cox regressionmodel used to analyze the likelihood of any treatment versus none
was stratiﬁed by pre-diagnosis GI events, so this variable was not included as a predictor.
211A. Modi et al. / Bone Reports 5 (2016) 208–213compliance (either negatively or positively) with anMPR ≥ 80%. Overall
comorbidity, i.e., the CCI score, was associated with bisphosphonate
treatment compliance, decreasing the likelihood of compliance at both
MPR ≥ 60% and MPR ≥ 80% (OR 0.94 [95% CI 0.90–0.99] for both levels;
Table 4).
4. Discussion
Our ﬁndings are consistent with previous reports on the treatment
of osteoporosis in Germany. The overall treatment rate of 16.9% in our
study was within the range of earlier studies. Using nationwide diagno-
sis and prescription claims data from 2000–2003, Haussler et al. found
that 24.7% of German women diagnosed with osteoporosis were pre-
scribed osteoporosis-speciﬁc therapy (Haussler et al., 2007). Among8.9%
30.8%
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Fig. 2. Frequency of GI events in patients initiatingpostmenopausal German women hospitalized for a distal radius frac-
ture in 2002–2003, 15.8% were receiving an anti-osteoporosis medica-
tion (Endres et al., 2007). Also like previous studies (Ziller et al., 2012;
Duarte et al., 2007), we found that bisphosphonates were the most
commonly prescribed pharmacotherapy in German osteoporosis
patients.
The GI event rates in our cohort 1 (13.8% pre-diagnosis, 14.8% post-
diagnosis) were on the low end of the range of GI events observed in
previous studies of German osteoporosis patients (14.5%–51.6%)
(Ringe and Moller, 2009; Bauer et al., 2012). Post-diagnosis GI events
in cohort 1 were signiﬁcantly predictive of non-treatment and of choos-
ing non-bisphosphonates over bisphosphonates. The former result
agreeswith the ﬁndings of Colon-Emeric et al., who found that US nurs-
ing home residents with esophagitis, peptic ulcer disease, or dysphagia
were less likely to receive treatment for osteoporosis (Colon-Emeric
et al., 2007). The latter result differs from those of Foster et al., who
found that diagnoses of peptic ulcer, dysphagia, reﬂux, or gastritis did
not alter the odds of receiving raloxifene versus bisphosphonates in
US women aged ≥45 insured commercially or via Medicare (Foster
et al., 2008). Our ﬁndings that older age and glucocorticoid use were
predictive of treatment in the year following an osteoporosis diagnosis
were consistent with a previous study of postmenopausal women in
the United States (Asche et al., 2010).
To our knowledge, no other studies have examined the association of
use of GI agents with the choice of treatment for osteoporosis. In this re-
gard, our study provides new insights into the role of gastroprotective
agents in the treatment of osteoporosis inGermany. It is somewhat coun-
terintuitive that use of these agents would increase the likelihood of os-
teoporosis treatment (Table 3), unless the explanation is that patients
already taking prescription medications are comfortable with taking ad-
ditionalmedications. However, the fact that gastroprotective agent use is
predictive of choosing non-bisphosphonates (Table 3) suggests that Ger-
man physicians anticipate GI problemswith bisphosphonates and adjust
their prescribing practices accordingly.
Regarding compliance, post-treatment GI events in cohort 2 de-
creased the odds of attaining a ≥60% MPR, but not a ≥80% MPR, with
an oral bisphosphonate. Evidence on the predictors of compliance
with oral bisphosphonates is mixed. In Dutch women taking
alendronate or risedronate, initiation of intestinal agents, but not of
gastroprotective agents, in the ﬁrst year of bisphosphonate administra-
tion was associated with increased odds of non-compliance (deﬁned as
anMPR ≤ 50%) (Penning-van Beest et al., 2008). Other studies of the as-
sociation of GI events with compliance have included men in the study
population (Gallagher et al., 2008) or analyzed a combined set of treat-
ments (e.g., oral and intramuscular bisphosphonates, calcium/vitamin
D, and raloxifene) (Rossini et al., 2006), precluding a direct comparison12.8%
19.1%
41.1%
53.2%
7.0%
12.0%
 months 12 months
07)
an oral bisphosphonate. GI, gastrointestinal.
Table 4
Likelihood of treatment compliance in patients initiating an oral bisphosphonate.
MPR ≥ 60%a MPR ≥ 80%a
Odds ratio 95% CI P value Odds ratio 95% CI P value
On-treatment GI events 0.84 0.73–0.97 0.016 0.91 0.79–1.06 0.234
Pre-treatment GI events 1.01 0.86–1.18 0.917 1.11 0.94–1.30 0.221
Age group (reference 55–64) b0.001 b0.001
65–74 0.94 0.81–1.10 0.96 0.83–1.12
75–84 0.99 0.85–1.15 0.93 0.80–1.09
≥85 0.98 0.80–1.22 0.86 0.69–1.08
Pre-treatment medication use
Gastroprotective agents 1.00 0.88–1.14 0.940 1.03 0.90–1.18 0.970
NSAIDs 1.15 1.04–1.27 0.009 1.10 0.99–1.23 0.069
Pre-treatment OP-related fractures 1.21 1.01–1.45 0.036 1.13 0.95–1.36 0.172
Deyo-Charlson comorbidity index 0.94 0.90–0.99 0.009 0.94 0.90–0.99 0.015
CI, conﬁdence interval; GI, gastrointestinal; MPR, medication possession ratio; NSAIDs, non-steroidal anti-inﬂammatory drugs; OP, osteoporosis.
a Bold font indicates statistical signiﬁcance.
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cant association of GI events or GI medication use with lower
compliance.
The primary limitation of this study is the use of medical claims as
the data source. Claims data are subject to errors of omission and com-
mission, and the assumption is that patients ﬁlling a prescription are ac-
tually taking the medication. Coding omissions may explain why the
prevalence of vitamin D deﬁciency (0.3%) in our study was low in com-
parison to other studies that report vitamin D deﬁciency in over 50% of
the German population (Hintzpeter et al., 2008; Rabenberg et al., 2015;
Ringe and Kipshoven, 2012). Another caveat is that our study included
almost twodecades of data fromaperiodduringwhichmany newphar-
macologic treatments for osteoporosis were approved for use in Europe.
While etidronate, alendronate, and raloxifenewere available during the
1990s, the rest of the therapies included in this study were only made
available in or after the year 2000 (Hernlund et al., 2013). The availabil-
ity of suitable treatments, aswell as the lag in uptake of new treatments,
reimbursement considerations, and evolving guidelines for treatment,
are all factors that would have affected the use of pharmacotherapies
for osteoporosis during this time period. The advent of injectable thera-
pies in the latter half of the 2000s has almost certainly altered patterns
of treatment initiation and types of treatment used. Our results should
therefore be interpreted within the limitations of the time period and
the data set from which they were derived. However, we note that the
combination of data fromall timeperiods provides insight into the over-
all effects of GI events on treatment with a wide array of therapies,
which reﬂects the current situation in Europe. The implications of this
for the current study are that the ﬁrst few years of the cohort 1 analysis
may be biased toward a larger percentage of untreated patients, because
the ﬁrst oral bisphosphonate did not appear in the Mediplus database
until 1996. Also, while cohort 1 included patients taking both injectable
and oral forms of bisphosphonates, cohort 2 was restricted to oral bis-
phosphonate users, so the results of the latter analyses are not applica-
ble to patients taking injectable forms of bisphosphonates; the results
should be interpreted with this in mind. We also note that the covari-
ates included in the logistic regression analyses of GI events do not com-
prise an exhaustive list of potential factors that physiciansmay consider
when prescribing anti-osteoporosis medication. Finally, our analysis
captured only GI events severe enough to warrant a physician visit, so
minor symptoms treated with over-the-counter medications would
not have been taken into account. This seems particularly appropriate
for cohort 2 in that patients with minor symptoms would probably be
less likely to discontinue medication because of them, compared to pa-
tients with more severe GI symptoms.
5. Conclusions
In conclusion, this study showed that GI events occurring in German
women newly diagnosed with osteoporosis decreased the likelihood oftreatment and altered the choice of treatment. Among thewomen initi-
ating oral bisphosphonates, post-treatment GI events decreased the
likelihood of patients attaining an MPR of ≥60%. Future studies could
shed more light on these issues by adjusting for the type and severity
of GI events in the regression analyses, by comparing the ﬁndings in
oral therapies versus injectable therapies, and by combining medical
claims data with patient self-reports to obtain a fuller picture of the ex-
perience of osteoporosis patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bonr.2016.06.001.
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